Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089205 | 0.91 | PTGES (0.56) | PTGESMCL1CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL3582187 | 0.87 | PTGES (0.67) | PTGESMCL1CYP1A2PPARDPIM3 | |
| SCHEMBL3570895 | 0.85 | PTGES (0.83) | PTGESMCL1PPARDBCL2MDM2 | |
| SCHEMBL4268491 | 0.84 | PTGES (0.60) | PTGESMCL1PPARDPIM3BCL2 | |
| SCHEMBL4101074 | 0.83 | PTGES (0.54) | PTGESMCL1CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL4097221 | 0.82 | PTGES (0.55) | PTGESMCL1PPARDBCL2MDM2 | |
| SCHEMBL4100038 | 0.82 | PTGES (0.60) | PTGESMCL1PPARDCYP3A4CYP3A5 | |
| SCHEMBL4096505 | 0.81 | PTGES (0.44) | PTGESMCL1CYP1A2PTPN11BCL2 | |
| Water SCHEMBL4923346 | 0.81 | PTGES (0.66) | PTGESMCL1PPARDBCL2MDM2 | |
| Water SCHEMBL4923358 | 0.81 | PTGES (0.66) | PTGESMCL1PPARDBCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1841766-A1 | PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077401-A1 | PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTGES 47/4885MCL1 1709/4885TDO2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.